Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?

KVUE reported adjusted operating margins of 23.1% in the first half of 2026, up 180 basis points year-over-year, while adjusted earnings climbed 18.9%. The profitability gains stem primarily from cost-cutting measures, offsetting sluggish top-line momentum: organic sales grew just 1.2% in the period.

Performance diverged across segments. Self Care struggled, while Skin Health and Beauty delivered stronger results. The company carries $8.5 billion in debt and faces ongoing pressure from tariffs and inflation.

KVUE's pending merger with KMB is expected to close in Q4 2026. The combination will consolidate two consumer health portfolios at a time when KVUE's margin expansion strategy appears to be working but revenue growth remains anemic. The deal's proximity—just one quarter away—adds a near-term catalyst for both names.

Investors weighing KVUE must balance proven margin discipline against tepid organic growth and significant leverage. The company is squeezing more profit from each dollar of sales, but it isn't growing the numerator meaningfully. The KMB merger timeline provides a concrete event horizon.